非小细胞肺癌MMP-3和TIMP-3表达与术后化疗及预后关系的研究  

Expression of MMP-3 and TIMP-3 in patients with non-small cell lung cancer and its relation to prognosis after chemotherapy

作　　者：嵇学仙 陈秋强[2] 石麒麟[3] 余欢明[2] 周骁[4] 辅恒钦[4] 嵇国平 

机构地区：[1]德清县人民医院病理科,313200 [2]湖州市第一人民医院胸外科 [3]湖州市第一人民医院病理科 [4]湖州市第一人民医院呼吸内科 [5]德清县人民医院呼吸内科,313200

出　　处：《浙江医学》2013年第17期1561-1564,共4页Zhejiang Medical Journal

基　　金：浙江省湖州市科技局一般科研社会发展项目(No.2010YSB07)

摘　　要：目的探讨Ⅱ～Ⅲ期非小细胞肺癌（NSCLC）患者肿瘤组织中MMP-3和TIMP-3的表达与术后接受含铂药物辅助化疗疗效的相关性。方法应用免疫组化方法检测112例NSCLC患者术后肿瘤组织中MMP-3和TIMP-3的表达，分析与化疗疗效和患者生存资料间的关系。结果患者肿瘤组织中MMP-3阳性率为5625％，TIMP-3阳性率为4732％，MMP-3阴性者术后生存优于阳性者；TIMP-3阴性者的术后生存低于阳性者（均P〈0．01）。MMP-3阴性同时TIMP-3阳性的患者术后使用铂类药物辅助化疗，生存时间可能延长。结论MMP-3和TIMP-3的表达可能作为NSCLC患者术后铂类药物化疗疗效及预后预测的参考指标。Objective TO investigate the expression of MMP-3, TIMP-3 in patients with non-small cell lung cancer （NSCLC） and its relation to the prognosis after chemotherapy. Methods Expression of MMP-3 and TIMP-3 in 112 paraffin-embedded pathological specimens of NSCLC were determined by immunohistochemistry method. All patients received platinum-based adjuvant chemotherapy after operation. The association of MMP-3 and TIMP-3 expression with response to chemotherapy and survival of patients were analyzed. Results Positive expression rates of MMP-3 and TIMP-3 were 56.25% and 47.32% in NSCLC patients, respectively. The survival time in MMP-3 negative group was longer than that in MMP-3 positive group（P〈O.01） and in TIMP-3 negative group was shorter than that in TIMP-3 positive group（P〈0.01）. Patients with negative expression of MMP-3 and positive expression of TIMP-3 showed a trend of improved survival time under platinum-based adjuvant chemotherapy. Conclusion The expression of MMP-3 and TIMP-3 is closely correlated with the survival time of NSCLC after adjuvant chemotherapy, indicating that MMP-3 and TIMP-3 can be used as molecular makers for prognosis f NSCLC patients.

关 键 词：非小细胞肺癌 基质金属蛋白酶-3 基质金属蛋白酶抑制剂-3 化疗 预后 

分 类 号：R734.2[医药卫生—肿瘤]